



ALLIA.143A

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant	:	Zaghouani, H.	)	Group Art Unit 1644
			)	
Appl. No.	:	09/779,767	)	I hereby certify that this correspondence and
			)	all marked attachments are being deposited
Filed	:	January 7, 1997	)	with the United States Postal Service as first
			)	class mail in an envelope addressed to:
For	:	Compounds, Compositions and	)	Commissioner of Patents and Trademarks,
		Methods for the Endocytic	)	Washington, D.C. 20231, on
		Presentation of Immunosuppressive	)	
		Factors	)	<u>12/19/2002</u>
			)	<u>Christine Hughey</u>
Examiner	:	P. Nolan	)	Christine Hughey

**AMENDMENT AND RESPONSE TO OFFICE ACTION**

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

In response to the Office Action dated October 21, 2002, applicant submits the following response:

**In the Claims:**

Please amend claim 66 as follows:

66. (Six times amended) A composition comprising an immunoglobulin or a portion thereof linked to a protein fragment or peptide, wherein said immunoglobulin or portion thereof is capable of binding to an Fc receptor and said protein fragment or peptide comprises a T cell receptor antagonist, said composition having the property of being endocytosed by cells bearing said Fc receptor and processed by the cells to present said T cell receptor antagonist in association with endogenous MHC Class II molecules, thereby preventing activation of autoreactive T cells *in vivo*.

RECEIVED  
APR 21 2003  
TECH CENTER 1600/2900